Urovant Sciences Ltd. Announces Pricing of Initial Public Offering
J.P. Morgan, Jefferies and Cowen are acting as joint book-running managers for the offering.
The offering will be made only by means of a prospectus. A copy of the final prospectus, when available, may be obtained from
A registration statement relating to these securities has been filed with, and declared effective by, the
About
Urovant is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Urovant's lead product candidate, vibegron, is an oral, once-daily, small molecule beta-3 agonist being evaluated in an international pivotal Phase 3 clinical trial for the treatment of overactive bladder. Urovant's second product candidate, hMaxi-K, is a novel gene therapy being developed for patients with overactive bladder who have failed oral pharmacological therapy.
Contacts
Investor inquiries: Investors@Urovant.com
Media inquiries: Media@Urovant.com
View original content:http://www.prnewswire.com/news-releases/urovant-sciences-ltd-announces-pricing-of-initial-public-offering-300719945.html
SOURCE